Copper-67 (Cu-67) is a promising therapeutic radionuclide that emits beta particles with a half-life of approximately 61.8 hours, making it exceptionally well-suited for targeted radionuclide therapy when conjugated to tumor-specific vectors such as peptides, antibodies, and small molecules. At Protheragen, we deliver specialized Cu-67 radiolabeling solutions designed to advance your radiopharmaceutical candidates from early-stage concept through preclinical validation and into IIT clinical studies, ensuring each project receives meticulous radiochemical attention.
Copper-67 decays exclusively via beta-minus emission (mean energy 141 keV, maximum 562 keV) with a physical half-life of 61.83 hours, depositing cytotoxic radiation over a tissue range of approximately 0.6–1.8 mm. This emission profile positions Cu-67 between high-energy beta emitters like Yttrium-90 and medium-energy emitters like Lutetium-177, offering a favorable balance between tumoricidal potency and sparing of adjacent healthy tissue. Importantly, Cu-67 also emits a 185 keV gamma photon in 49% of decays, enabling concurrent SPECT imaging for dosimetry and treatment monitoring without requiring a separate diagnostic isotope. The well-established coordination chemistry of copper allows seamless incorporation of Cu-67 into diverse bioconjugates using macrocyclic chelators such as DOTA, NOTA, and the increasingly favored SarAr (sarcophagine) derivatives, which demonstrate superior in vivo stability compared to earlier-generation ligands.
Fig 1. Decay schemes of 64Cu (A) and 67Cu (B). (Zhang, Siqi, et al., 2025)
The Cu-67/Cu-64 theranostic pair has gained substantial traction in contemporary nuclear medicine. While Cu-64 (half-life 12.7 hours, positron emitter) serves as the diagnostic counterpart for PET imaging and dosimetry calculations, Cu-67 delivers the therapeutic payload, enabling personalized treatment planning based on individual patient pharmacokinetics. This matched-pair approach eliminates uncertainties arising from using chemically different elements for imaging and therapy, ensuring that the diagnostic scan genuinely reflects the biodistribution of the therapeutic agent. Preclinical studies have demonstrated the efficacy of Cu-67-labeled PSMA ligands in prostate cancer models, Cu-67-SAR-TATE in neuroendocrine tumors, and Cu-67-labeled antibodies in colorectal and breast cancer xenografts, with several programs now advancing toward clinical evaluation.
| Trend | Key Developments | Impact on Cu-67 Programs |
|---|---|---|
| Theranostics Expansion | Matched diagnostic/therapeutic isotope pairs (e.g., 64Cu/67Cu, 68Ga/177Lu) enabling personalized dosing and real-time treatment monitoring. | Directly leverages the Cu-64/Cu-67 pair for seamless imaging-to-therapy translation. |
| Targeted Alpha Therapy (TAT) Growth | Actinium-225 and Lead-212 agents gaining regulatory traction; combination approaches with beta emitters being explored. | Positions Cu-67 as a complementary beta-emitting option in combination regimens. |
| Novel Chelator Development | SarAr, cross-bridged chelators, and bifunctional variants offering enhanced kinetic inertness and reduced trans-chelation. | Improves Cu-67 complex stability, minimizing hepatic accumulation and off-target toxicity. |
| Automated Production & GMP Scale-Up | Modular synthesizers, microfluidic platforms, and AI-driven process optimization reducing batch-to-batch variability. | Enables reliable, reproducible Cu-67 radiolabeling for clinical-grade material supply. |
| Expanded Indications Beyond Oncology | Neurology, cardiology, and inflammatory disease applications emerging; radiopharmaceuticals for amyloid and tau imaging advancing. | Creates opportunities for Cu-67 therapy in non-oncology indications as targeting ligands mature. |
| Supply Chain Resilience | Localized cyclotron production, photo-nuclear routes, and target recycling programs reducing isotope shortages. | Improves Cu-67 accessibility for multi-center clinical trials and commercial manufacturing. |
Protheragen operates as a dedicated radiopharmaceutical CRDMO and CRO, bridging the gap between radiochemical innovation and clinical translation. Our Cu-67 radiolabeling service is embedded within a comprehensive radiochemistry platform that encompasses isotope sourcing, conjugation chemistry, radiolabeling optimization, quality control, and preclinical evaluation. Whether your program requires small-scale proof-of-concept radiolabeling for lead selection or GMP-compliant production for IIT clinical trials, our multidisciplinary team—comprising radiochemists, analytical scientists, and regulatory specialists—collaborates closely with you to define specifications, troubleshoot challenges, and deliver material that meets the exacting standards of modern nuclear medicine. From peptide-based vectors to full-length monoclonal antibodies and engineered nanoparticles, we adapt our radiolabeling protocols to the unique physicochemical properties of each targeting moiety, ensuring high specific activity, excellent radiochemical purity, and batch-to-batch consistency.
We assist in selecting and installing optimal chelators—DOTA, NOTA, NODAGA, or SarAr derivatives—onto your targeting ligands via well-defined conjugation chemistries. Our team evaluates conjugation efficiency, chelator-to-ligand ratios, and potential impact on receptor binding affinity through in vitro assays before proceeding to radiolabeling.
Our radiochemistry laboratory performs Cu-67 radiolabeling under rigorously controlled conditions, optimizing parameters including pH, temperature, reaction time, and ligand concentration to achieve maximal radiochemical yield and specific activity. We routinely handle challenging substrates including heat-sensitive peptides and large proteins, employing mild labeling conditions that preserve biological function.
Every Cu-67 radiolabeling batch undergoes comprehensive analytical characterization:
Leveraging our in vivo imaging infrastructure, we offer SPECT/CT imaging and ex vivo biodistribution studies to validate tumor targeting, estimate normal organ radiation doses, and establish pharmacokinetic profiles for your Cu-67 radiopharmaceutical. These data directly inform human dosimetry projections and clinical trial design.
For programs transitioning into investigator-initiated trials, we provide clinical-grade Cu-67 radiopharmaceutical manufacturing with full documentation packages, including batch records, certificates of analysis, and stability data, aligned with applicable regulatory expectations for radiopharmaceutical investigational products.
We offer integrated development of the Cu-64 diagnostic counterpart alongside your Cu-67 therapeutic agent, ensuring identical targeting ligands and chelation chemistry. This matched-pair strategy enables accurate pre-therapy dosimetry, patient selection, and post-treatment response assessment using the same molecular platform.
Our streamlined workflow is designed to accelerate your radiopharmaceutical program while maintaining the highest radiochemical and quality standards. Each project begins with a detailed technical consultation and progresses through systematic development, optimization, and delivery phases.
1. Project Consultation and Feasibility Assessment
We review your targeting ligand structure, proposed indication, and development stage to recommend the most suitable chelator, labeling strategy, and analytical package. A formal proposal with timelines and deliverables is provided for your approval.
2. Ligand Conjugation and Pre-Labeling Characterization
Your targeting molecule is conjugated with the selected bifunctional chelator under optimized conditions. The resulting bioconjugate is characterized by mass spectrometry, HPLC, and receptor binding assays to confirm integrity and functionality before radiolabeling.
3. Cu-67 Radiolabeling and Reaction Optimization
Radiolabeling is performed using no-carrier-added Cu-67 chloride in buffered aqueous solution. We systematically optimize pH (typically 4.5–6.5), temperature (room temperature to 95°C depending on chelator), and reaction time to achieve >95% radiochemical yield with minimal free isotope.
4. Purification and Formulation
The radiolabeled product is purified by size-exclusion chromatography, solid-phase extraction, or HPLC as appropriate, then formulated in a suitable buffer (e.g., 0.9% saline, PBS, or acetate buffer) with optional addition of stabilizers such as gentisic acid or ascorbate to minimize radiolytic degradation.
5. Comprehensive Quality Control Release
The final product undergoes a full QC panel including radiochemical purity, pH, osmolality, endotoxin, sterility (when applicable), and stability testing. A certificate of analysis is issued with each batch.
6. Preclinical or Clinical Distribution
Released material is dispatched under appropriate radioactive materials shipping protocols to your preclinical facility or clinical site, accompanied by full documentation and radiation safety guidance.
If you are developing a Cu-67 radiopharmaceutical candidate and require expert radiolabeling support—from initial conjugation chemistry through clinical-grade production—reach out to us today to discuss your project specifications. Our radiochemistry team is prepared to evaluate your targeting ligand, propose an optimized labeling strategy, and provide a detailed timeline and quotation tailored to your development objectives. Contact us now to accelerate your radiopharmaceutical program with Protheragen's specialized Cu-67 radiolabeling expertise.
Reference